1.

作为晚期非小细胞肺癌治疗选择的分子靶向药物指定联合的临床研发

Clinical development of selected combinations of molecular targeted agents as treatment options for advanced non-small-cell lung cancer

药物联合	临床前	Ⅰ/Ⅱ期	Ⅲ期
Abbreviations: EGFR=epidermal growth factor receptor; IGF-1R=insulin-like growth factor receptor-1; mTOR=mammalian target of rapamycin; NSCLC= non-small-cell lung cancer; VDA=vascular disrupting agents; VEGF=vascular endothelial growth factor. Note: Reprinted with permission from the copyright holder©CIG Media Group, LP 缩写：EGFR：表皮生长因子受体；IGF-1R：胰岛素样生长因子Ⅰ型受体；mTOR：哺乳类动物雷帕霉素靶蛋白；NSCLC：非小细胞肺癌；VDA：血管破坏剂；VEGF：血管内皮生长因子。 注：本图得到版权所有者©CIG Media Group, LP复制许可
EGFR+VEGF	√[6, 7]	√[15, 16]	在研[23, 24]
EGFR+mTOR	√[8-10]	在研[17-19]	—
EGFR+IGF-1R	√[11]	在研[20]	在研[25]
VEGF+VDA	√[12, 13]	在研[21]	—
mTOR+IGF-1R	√[14]	在研[22]